abatacept,tocilizumab,rituximab
jw pharma,bms,roche
['rituximab', 'toci', 'tocilizumab', 'ritux', 'abatacept']
composite endpoints may be superior to essdai due to lower placebo response and better discrimination between placebo and active treatment in #sjogrens #eular2023 #rheumtwitter 
Tweeting anything #Rheum #COVID19
MD | PhD | Clinical Associated Professor | Rheumatology #RheumTwitter #ACRAmbassador for #ACR22